<DOC>
	<DOCNO>NCT00850005</DOCNO>
	<brief_summary>This project address vex problem allude best effort medical/scientific community : treatment resistant neuropathic pain . Neuropathic pain common include condition diabetic neuropathy , post herpetic neuralgia post stroke pain believe affect least 3 % adult . Surveys patient neuropathic pain indicate 60 % receive adequate relief current treatment . Results recent laboratory human study reveal new approach treatment . This approach base finding neuroinflammation appear involve development maintenance neuropathic pain . This study explore effect immune-modulating blood-derived product , intravenous immunoglobulin ( IVIG ) , treat neuropathic pain . IVIG think reduce neuroinflammation contribute neuropathic pain . If successful , study provide important insight pain mechanism well understand IVIG relief neuropathic pain . Hypotheses : 1 . Reduction neuroinflammation ( NI ) markers co-vary clinical indicator pain relief 2 . Patients high level marker NI likely respond IVIG</brief_summary>
	<brief_title>Intravenous Immunoglobulin ( IVIG ) Resistant Neuropathic Pain</brief_title>
	<detailed_description>This study employ randomize double blind cross-over design . A total 12 subject recruit study . Once subject satisfied inclusion exclusion criterion provide informed consent , subject randomize either IVIG placebo treatment group , use pre-determined randomization list generate research office University Calgary . Complete responder begin monitor phase , partial non-responders return second cycle one month . Complete responder , prolonged relief , cross-over alternative treatment pain return occur within 6 month infusion .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Age &gt; 18 year ; Clinical diagnosis treatmentresistant neuropathic pain ; Score 4/10 great DN4 NeP screen questionnaire ; Bedside examination confirm symptom neuropathic pain ; Moderate severe pain ; Completed adequate analgesic trial accord neuropathic pain clinical practice guideline ; provide informed consent Pregnant lactate woman ; Clinical diagnosis phantom limb pain ; History psychosis ; current , substance dependency disorder ; presence clinically significant cardiac pulmonary disorder would compromise participant ' safety ; severe pain disorder chronic NeP study ; Abnormalities 1.5 time upper range normal screen CBC , blood chemistry ; Serum IgA less &lt; 0.05 g/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>neuropathic pain</keyword>
	<keyword>resistant</keyword>
	<keyword>neuroinflammation</keyword>
	<keyword>neuroinflammatory marker</keyword>
	<keyword>Neuropathic pain respond standard therapy</keyword>
</DOC>